Merck, Santen deal

Merck will divest rights to nine ophthalmic products to Santen in countries in Europe and Asia-Pacific. Merck said the products, which includes Cosopt dorzolamide and Cosopt PF for intraocular pressure (IOP), had sales of about $400 million in 2013 in the markets covered by the deal. Merck will receive about $600 million up front and is

Read the full 563 word article

How to gain access

Continue reading with a
two-week free trial.